Montreal-based Pharmascience has announced the launch of its pms-fluticasone propionate/salmeterol DPI in Canada for the treatment of asthma and COPD. The company says that the DPI uses the same device as Advair Diskus.
According to the Health Canada Drug Product Database, three strengths of pms-fluticasone propionate/salmeterol DPI (100mcg/50mcg, 250mcg/50mcg, and 500mcg/50mcg) are being marketed as of March 5, 2020.
Pharmascience Canada VP and General Manager Al Moghaddam, commented, “Pharmascience is proud to launch this important product and to be bringing a lower cost alternative solution to this very complex market. We continue to build our respiratory franchise and are committed to patients and other stakeholders. The launch of pms-fluticasone propionate/salmeterol DPI reflects our corporate commitment to the Canadian community.”
Read the Pharmascience press release.
